Ipamorelin Studies Guide: Selective GH Secretagogue

Ipamorelin is a cyclic pentapeptide developed by Novo Nordisk in the late 1990s as a growth hormone secretagogue. Its defining characteristic — and the reason it has become the most widely studied GHRP in modern peptide science — is its exceptional selectivity: it stimulates robust growth hormone release through the pituitary ghrelin receptor without meaningfully elevating cortisol, prolactin, ACTH, or aldosterone.

This selectivity solved a fundamental problem with earlier GH secretagogues and made Ipamorelin the preferred GHSR agonist for protocols where hormonal precision matters.

What Is Ipamorelin?

Ipamorelin is a 5-amino acid cyclic peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as an agonist at the Growth Hormone Secretagogue Receptor 1a (GHSR-1a), also known as the ghrelin receptor. Its cyclic structure and D-amino acid substitutions confer stability against enzymatic degradation and high receptor selectivity.

| Property | Value | |----------|-------| | Classification | Cyclic pentapeptide GHRP | | Receptor target | GHSR-1a (ghrelin receptor) | | Molecular weight | ~711 Da | | Half-life | ~2 hours (SC administration) | | Time to peak GH | 15–30 minutes | | GH pulse duration | 2–3 hours | | Selectivity | Very high — minimal off-target effects |

Why Ipamorelin Is Selective: The Mechanism

Ipamorelin's selectivity stems from its precise receptor binding profile.

Receptor Mechanism

When Ipamorelin binds GHSR-1a on pituitary somatotroph cells, it activates the Gαq/11 protein signaling cascade:

1. Gαq/11 activation → Phospholipase C (PLC) activation
2. PLC cleaves PIP2 → produces IP3 and DAG
3. IP3 triggers calcium release from the endoplasmic reticulum
4. Calcium-dependent exocytosis of GH-containing secretory granules
5. Result: Clean, pulsatile GH release

Why doesn't cortisol go up? Earlier GHRPs like GHRP-2 and GHRP-6 have significant binding affinity for multiple receptor subtypes beyond GHSR-1a — including receptors that mediate ACTH and cortisol release. Ipamorelin's molecular design achieves much higher selectivity for GHSR-1a over these other receptor types, producing GH release without activating the ACTH/cortisol pathway.

GHSR-1a vs. Cortisol/Prolactin Pathway

The cortisol and prolactin-elevating effects of older GHRPs are mediated through:

• ACTH release (which drives cortisol from the adrenal gland)
• Direct prolactin release from pituitary lactotrophs

Ipamorelin's tight GHSR-1a selectivity avoids activating these pathways, producing a hormonal profile significantly cleaner than GHRP-2 or GHRP-6.

Selectivity Comparison: Ipamorelin vs. Other GH Peptides

| Compound | GH Release | Cortisol Elevation | Prolactin Elevation | ACTH Elevation | Route | |----------|-----------|---------------------|---------------------|----------------|-------| | Ipamorelin | +++ | Minimal | Minimal | Minimal | SC injection | | GHRP-2 | ++++ | Moderate | Significant | Moderate | SC injection | | GHRP-6 | +++ | Significant | Significant | Significant | SC injection | | Sermorelin | ++ | Minimal | Minimal | Minimal | SC injection | | MK-677 (Ibutamoren) | +++ | Minimal | Slight | Minimal | Oral | | CJC-1295 | ++ | Minimal | Minimal | Minimal | SC injection |

Ipamorelin achieves the best balance of GH stimulation potency and hormonal selectivity of any injectable GHRP, making it the reference compound for selective GH pulse studies.

Key Studies Findings

Original Novo Nordisk Characterization (Raun et al., 1998)

The foundational Ipamorelin study — published by its developers — demonstrated in rat models that Ipamorelin produced robust, dose-dependent GH release while showing no significant elevation of cortisol, prolactin, or ACTH at doses up to 500 mcg/kg. This selectivity profile, unprecedented among GHRPs at the time, distinguished Ipamorelin from all prior compounds in its class.

Dose-Response in Large Animals (Johansen et al., 1999)

A subsequent study in pigs characterized the dose-response relationship for Ipamorelin. Key findings:

• Clear dose-dependent GH stimulation from 1–500 mcg/kg
• No adverse hormonal effects at any dose tested
• GH response consistent across repeated administrations (no rapid desensitization)

Body Composition Studies

Rodent studies using Ipamorelin over 8–24 weeks consistently show GH-mediated body composition changes:

• Increased lean body mass
• Reduced adipose tissue accumulation
• Improved bone mineral density markers (consistent with GH/IGF-1 effects on bone remodeling)

Bone Density Studies

Studies specifically examining Ipamorelin's effects on bone in rats demonstrated improvements in bone mineral density and bone strength markers after 12 weeks of treatment — effects consistent with the well-established role of GH and IGF-1 in bone metabolism.

IGF-1 Elevation

Consistent with its GH-stimulating mechanism, Ipamorelin reliably elevates IGF-1 (Insulin-like Growth Factor 1) in treated animals. IGF-1 is the primary downstream mediator of most GH effects (lean mass, bone, recovery) and serves as the most commonly used biomarker for assessing GH activity in protocols.

Dosing Protocols

| Protocol Type | Dose Per Injection | Frequency | Timing | Duration | |--------------|-------------------|-----------|--------|----------| | Conservative | 100 mcg | 1x daily | Pre-sleep | 8–12 weeks | | Standard | 200 mcg | 2–3x daily | Fasted; pre-sleep | 12–24 weeks | | Intensive | 300 mcg | 3x daily | Morning, afternoon, pre-sleep | 12–24 weeks | | Stack with CJC-1295 | 200 mcg (Ipa) + 100–200 mcg (CJC) | 2–3x/week | Pre-sleep, fasted | 12–24 weeks |

Key Timing Considerations

Fasted state: Insulin directly blunts GH release. Ipamorelin should be administered at least 2–3 hours after the last meal, and 30–60 minutes should elapse before eating after injection to allow the GH pulse to develop unimpeded.

Pre-sleep timing: GH release naturally peaks during slow-wave sleep. Pre-sleep Ipamorelin administration amplifies this natural nocturnal GH surge. This is the most commonly cited optimal timing in GH peptide protocols.

Multiple daily dosing: Some protocols use 2–3 daily Ipamorelin injections to produce multiple GH pulses throughout the day, mimicking the natural pulsatile GH secretion pattern more closely.

Stacking with CJC-1295

Ipamorelin is most frequently combined with a GHRH analog — most commonly CJC-1295 without DAC — in a synergistic stack that activates both the GHRHR and GHSR-1a pathways simultaneously.

The principle: GHRH receptor activation (CJC-1295) and GHSR activation (Ipamorelin) converge on the same GH secretory machinery through upstream pathways that amplify each other. Combined administration produces GH pulses 5–10x larger than Ipamorelin alone, while Ipamorelin's selectivity keeps the hormonal profile clean.

Typical combined dosing:

• Ipamorelin: 100–200 mcg per injection
• CJC-1295 (no DAC): 100–200 mcg per injection
• Injected simultaneously (can be combined in one syringe)
• 2–3x per week or once daily pre-sleep

View Ipamorelin | View CJC-1295 | View Sermorelin

Comparison with MK-677

MK-677 (Ibutamoren) is an oral, non-peptide ghrelin receptor agonist that produces similar GH/IGF-1 elevations but with several key differences:

| Property | Ipamorelin | MK-677 | |----------|-----------|--------| | Route | SC injection | Oral | | Half-life | ~2 hours | ~24 hours | | GH pattern | Pulsatile (2–3 hour window) | Sustained elevation (24-hour) | | IGF-1 elevation | Dose-dependent | Consistent 40–80% increase | | Cortisol impact | Minimal | Minimal | | Water retention | Less common | More common | | Appetite stimulation | Minimal | Significant | | Convenience | Injection required | Once-daily oral |

Ipamorelin's shorter half-life and pulsatile GH pattern more closely mimic physiological GH secretion. MK-677's oral bioavailability and once-daily dosing provide convenience advantages. Many protocols use one or the other based on the specific study endpoint and administration preference.

View MK-677

Storage and Reconstitution

Lyophilized Ipamorelin:

• Refrigerate at 2–8°C; stable 12–18 months
• Long-term storage: freeze at -20°C

Reconstituted Ipamorelin:

• Reconstitute in bacteriostatic water
• Standard concentration: 2 mg vial + 2 mL BAC water = 1000 mcg/mL
• 200 mcg dose = 0.2 mL (20 units on U-100 syringe)
• Store at 2–8°C after reconstitution
• Use within 28–30 days

Studies Disclaimer

Important: All information in this guide is provided for educational and educational purposes only. Ipamorelin is not approved by the FDA or any regulatory body for human therapeutic use. It is sold exclusively for laboratory use. This guide does not constitute medical advice. Always consult a licensed healthcare provider before considering any peptide-related protocol.